Rani Therapeutics Holdings (RANI) Receivables (2020 - 2026)

Rani Therapeutics Holdings has reported Receivables for 4 years, with the latest figure at $2.0 million in Q2 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $2.0 million in Q2 2026; TTM through Jun 2026 was $2.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.0 million, up 146.62% from the prior year.
• Receivables was $2.0 million for Q2 2026 at Rani Therapeutics Holdings, roughly flat from $2.0 million in the prior quarter.
• The five-year high for Receivables was $2.0 million in Q4 2025, with the low at $600000.0 in Q1 2025.
• Average Receivables over 3 years is $1.5 million, with a median of $2.0 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Receivables surged 146.62% in 2025, then soared 240.33% in 2026.
• Over 3 years, Receivables stood at $828000.0 in 2024, then soared by 146.62% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
• The last three Receivables figures came in at $2.0 million (Q2 2026), $2.0 million (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.